202 related articles for article (PubMed ID: 22954060)
1. Estimating the economic benefits of positive shifts in fibromyalgia severity: an exploratory analysis based on modeling of clinical trial data of pregabalin.
Cappelleri JC; Bushmakin AG; Zlateva G; Chandran A
J Med Econ; 2013; 16(1):55-61. PubMed ID: 22954060
[TBL] [Abstract][Full Text] [Related]
2. Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine.
Harnett J; Margolis J; Cao Z; Fowler R; Sanchez RJ; Mardekian J; Silverman SL
Pain Pract; 2011; 11(3):217-29. PubMed ID: 21199319
[TBL] [Abstract][Full Text] [Related]
3. Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population.
Udall M; Louder A; Suehs BT; Cappelleri JC; Joshi AV; Patel NC
J Med Econ; 2013; 16(6):784-92. PubMed ID: 23565813
[TBL] [Abstract][Full Text] [Related]
4. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia.
Pauer L; Winkelmann A; Arsenault P; Jespersen A; Whelan L; Atkinson G; Leon T; Zeiher B;
J Rheumatol; 2011 Dec; 38(12):2643-52. PubMed ID: 21965636
[TBL] [Abstract][Full Text] [Related]
5. The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome.
Russell IJ; Crofford LJ; Leon T; Cappelleri JC; Bushmakin AG; Whalen E; Barrett JA; Sadosky A
Sleep Med; 2009 Jun; 10(6):604-10. PubMed ID: 19410509
[TBL] [Abstract][Full Text] [Related]
6. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia.
Zhao Y; Sun P; Watson P; Mitchell B; Swindle R
Pain Pract; 2011; 11(3):204-16. PubMed ID: 20807351
[TBL] [Abstract][Full Text] [Related]
7. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia.
Arnold LM; Russell IJ; Diri EW; Duan WR; Young JP; Sharma U; Martin SA; Barrett JA; Haig G
J Pain; 2008 Sep; 9(9):792-805. PubMed ID: 18524684
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia.
Mease PJ; Russell IJ; Arnold LM; Florian H; Young JP; Martin SA; Sharma U
J Rheumatol; 2008 Mar; 35(3):502-14. PubMed ID: 18278830
[TBL] [Abstract][Full Text] [Related]
9. Minimal clinically important difference in the fibromyalgia impact questionnaire.
Bennett RM; Bushmakin AG; Cappelleri JC; Zlateva G; Sadosky AB
J Rheumatol; 2009 Jun; 36(6):1304-11. PubMed ID: 19369473
[TBL] [Abstract][Full Text] [Related]
10. Health care costs in patients with fibromyalgia on pregabalin vs. duloxetine.
Burke JP; Sanchez RJ; Joshi AV; Cappelleri JC; Kulakodlu M; Halpern R
Pain Pract; 2012 Jan; 12(1):14-22. PubMed ID: 21615857
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the fibromyalgia impact questionnaire at baseline as a predictor for time to pain improvement in two clinical trials of pregabalin.
Bushmakin AG; Cappelleri JC; Chandran AB; Zlateva G
Int J Clin Pract; 2013 Jan; 67(1):52-9. PubMed ID: 23241048
[TBL] [Abstract][Full Text] [Related]
12. Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care.
Gore M; Tai KS; Chandran A; Zlateva G; Leslie D
J Med Econ; 2012; 15(1):19-31. PubMed ID: 21970699
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin.
Gore M; Sadosky AB; Zlateva G; Clauw DJ
Pain Pract; 2009; 9(5):363-74. PubMed ID: 19500273
[TBL] [Abstract][Full Text] [Related]
14. Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators.
Sun P; Peng X; Sun S; Novick D; Faries DE; Andrews JS; Wohlreich MM; Wu A
Pain Pract; 2014 Jan; 14(1):22-31. PubMed ID: 23489659
[TBL] [Abstract][Full Text] [Related]
15. Relationships among pain and depressive and anxiety symptoms in clinical trials of pregabalin in fibromyalgia.
Arnold LM; Leon T; Whalen E; Barrett J
Psychosomatics; 2010; 51(6):489-97. PubMed ID: 21051680
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of pharmacologic treatment of fibromyalgia in Mexico.
Arreola Ornelas H; Rosado Buzzo A; García L; Dorantes Aguilar J; Contreras Hernández I; Mould Quevedo JF
Reumatol Clin; 2012; 8(3):120-7. PubMed ID: 22386298
[TBL] [Abstract][Full Text] [Related]
17. Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia.
Arnold LM; Emir B; Murphy TK; Zeiher BG; Pauer L; Scott G; Petersel D
Clin Ther; 2012 May; 34(5):1092-102. PubMed ID: 22503162
[TBL] [Abstract][Full Text] [Related]
18. Long-term maintenance of response across multiple fibromyalgia symptom domains in a randomized withdrawal study of pregabalin.
Pauer L; Atkinson G; Murphy TK; Petersel D; Zeiher B
Clin J Pain; 2012 Sep; 28(7):609-14. PubMed ID: 22688598
[TBL] [Abstract][Full Text] [Related]
19. Effect of pregabalin in the treatment of refractory neck pain: cost and clinical evidence from medical practice in orthopedic surgery and rehabilitation clinics.
Flórez-García M; Ceberio-Balda F; Morera-Domínguez C; Masramón X; Pérez M
Pain Pract; 2011; 11(4):369-80. PubMed ID: 21199310
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective.
Lloyd A; Boomershine CS; Choy EH; Chandran A; Zlateva G
J Med Econ; 2012; 15(3):481-92. PubMed ID: 22339078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
